Compare SNAL & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNAL | QNRX |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.2M | 17.8M |
| IPO Year | 2022 | 2023 |
| Metric | SNAL | QNRX |
|---|---|---|
| Price | $2.34 | $3.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $20.38 |
| AVG Volume (30 Days) | ★ 150.0K | 9.3K |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $81,225,622.00 | N/A |
| Revenue This Year | $25.62 | N/A |
| Revenue Next Year | $7.81 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.59 | $3.25 |
| 52 Week High | $21.60 | $23.50 |
| Indicator | SNAL | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 52.03 | 31.80 |
| Support Level | $1.92 | N/A |
| Resistance Level | $2.63 | $5.18 |
| Average True Range (ATR) | 0.31 | 0.28 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 46.55 | 6.03 |
Snail Inc is an independent developer and publisher of interactive digital entertainment for consumers around the world, with a portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States. The Company has one operating and reportable segment. The company operates in the USA, the UK and Other Countries.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.